305 related articles for article (PubMed ID: 19832922)
1. PSA at postoperative three months can predict biochemical recurrence in patients with pathological T3 prostate cancer following radical prostatectomy.
Inagaki T; Kohjimoto Y; Nishizawa S; Kuramoto T; Nanpo Y; Fujii R; Matsumura N; Shintani Y; Uekado Y; Hara I
Int J Urol; 2009 Dec; 16(12):941-6. PubMed ID: 19832922
[TBL] [Abstract][Full Text] [Related]
2. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
3. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
4. Seminal vesicle involvement after radical prostatectomy: predicting risk factors for progression.
Salomon L; Anastasiadis AG; Johnson CW; McKiernan JM; Goluboff ET; Abbou CC; Olsson CA; Benson MC
Urology; 2003 Aug; 62(2):304-9. PubMed ID: 12893340
[TBL] [Abstract][Full Text] [Related]
5. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
6. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
[TBL] [Abstract][Full Text] [Related]
7. Lymphovascular invasion is an independent prognostic factor in prostatic adenocarcinoma.
Cheng L; Jones TD; Lin H; Eble JN; Zeng G; Carr MD; Koch MO
J Urol; 2005 Dec; 174(6):2181-5. PubMed ID: 16280760
[TBL] [Abstract][Full Text] [Related]
8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
9. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
10. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
[TBL] [Abstract][Full Text] [Related]
11. Can perineural invasion on prostate needle biopsy predict prostate specific antigen recurrence after radical prostatectomy?
de la Taille A; Rubin MA; Bagiella E; Olsson CA; Buttyan R; Burchardt T; Knight C; O'Toole KM; Katz AE
J Urol; 1999 Jul; 162(1):103-6. PubMed ID: 10379750
[TBL] [Abstract][Full Text] [Related]
12. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
13. Conformal radiotherapy for detectable PSA following radical prostatectomy: efficacy and predictive factors of recurrence.
Delongchamps NB; Zerbib M; Mejean A; Rouach Y; Debre B; Peyromaure M
Can J Urol; 2009 Oct; 16(5):4813-9. PubMed ID: 19796456
[TBL] [Abstract][Full Text] [Related]
14. Percent of cores positive for cancer is a better preoperative predictor of cancer recurrence after radical prostatectomy than prostate specific antigen.
San Francisco IF; Regan MM; Olumi AF; DeWolf WC
J Urol; 2004 Apr; 171(4):1492-9. PubMed ID: 15017206
[TBL] [Abstract][Full Text] [Related]
15. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
[TBL] [Abstract][Full Text] [Related]
16. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
[TBL] [Abstract][Full Text] [Related]
17. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.
Lughezzani G; Gallina A; Larcher A; Briganti A; Capitanio U; Suardi N; Lista G; Abrate A; Sangalli MN; Buffi N; Cestari A; Guazzoni G; Rigatti P; Montorsi F
BJU Int; 2013 May; 111(5):723-30. PubMed ID: 22487441
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of the nadir value of serum prostate-specific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.
Sakai I; Harada K; Kurahashi T; Muramaki M; Yamanaka K; Hara I; Inoue TA; Miyake H
Urol Int; 2006; 76(3):227-31. PubMed ID: 16601384
[TBL] [Abstract][Full Text] [Related]
19. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
[TBL] [Abstract][Full Text] [Related]
20. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
